{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:36:29Z","timestamp":1760783789145,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Cape Town Neurology Fund"},{"DOI":"10.13039\/501100004513","name":"Harry Crossley research foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004513","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.nmd.2014.02.010","type":"journal-article","created":{"date-parts":[[2014,3,6]],"date-time":"2014-03-06T18:15:57Z","timestamp":1394129757000},"page":"499-508","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["The effects of prednisone and steroid-sparing agents on decay accelerating factor (CD55) expression: Implications in myasthenia gravis"],"prefix":"10.1016","volume":"24","author":[{"given":"Jennifer","family":"Auret","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amaal","family":"Abrahams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Prince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeannine M.","family":"Heckmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2014.02.010_b0005","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1749-6632.1987.tb51291.x","article-title":"Complement-mediated muscle damage produced by myasthenic sera","volume":"505","author":"Childs","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.nmd.2014.02.010_b0010","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1196\/annals.1405.037","article-title":"Extraocular muscle susceptibility to myasthenia gravis: unique immunological environment?","volume":"1132","author":"Soltys","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.nmd.2014.02.010_b0015","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2249.2006.03205.x","article-title":"The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice","volume":"146","author":"Morgan","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.nmd.2014.02.010_b0020","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.expneurol.2004.06.005","article-title":"Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis","volume":"189","author":"Kaminski","year":"2004","journal-title":"Exp Neurol"},{"key":"10.1016\/j.nmd.2014.02.010_b0025","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2012.01.003","article-title":"DAF\/CD55 and protectin\/CD59 modulate adaptive immunity and disease outcome in experimental autoimmune myasthenia gravis","volume":"244","author":"Soltys","year":"2012","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.nmd.2014.02.010_b0030","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.expneurol.2006.06.003","article-title":"Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia","volume":"202","author":"Kaminski","year":"2006","journal-title":"Exp Neurol"},{"key":"10.1016\/j.nmd.2014.02.010_b0035","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.it.2005.12.008","article-title":"Holding T cells in check \u2013 a new role for complement regulators?","volume":"27","author":"Longhi","year":"2006","journal-title":"Trends Immunol"},{"key":"10.1016\/j.nmd.2014.02.010_b0040","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/eji.200323381","article-title":"CD55\/decay accelerating factor is part of the lipopolysaccharide-induced receptor complex","volume":"33","author":"Heine","year":"2003","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.nmd.2014.02.010_b0045","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1046\/j.1365-2567.2003.01733.x","article-title":"Decay-accelerating factor induction by tumour necrosis factor-alpha, through a phosphatidylinositol-3 kinase and protein kinase C-dependent pathway, protects murine vascular endothelial cells against complement deposition","volume":"110","author":"Ahmad","year":"2003","journal-title":"Immunology"},{"key":"10.1016\/j.nmd.2014.02.010_b0050","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1365-2567.1997.00358.x","article-title":"Tumour necrosis factor-alpha up-regulates decay-accelerating factor gene expression in human intestinal epithelial cells","volume":"90","author":"Andoh","year":"1997","journal-title":"Immunology"},{"key":"10.1016\/j.nmd.2014.02.010_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/gene.2009.61","article-title":"A functional SNP in the regulatory region of the decay-accelerating factor gene associates with extraocular muscle pareses in myasthenia gravis","volume":"11","author":"Heckmann","year":"2010","journal-title":"Genes Immun"},{"key":"10.1016\/j.nmd.2014.02.010_b0060","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.nmd.2007.07.002","article-title":"Myasthenia gravis in South Africans: racial differences in clinical manifestations","volume":"17","author":"Heckmann","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2014.02.010_b0065","doi-asserted-by":"crossref","first-page":"532","DOI":"10.7196\/SAMJ.5390","article-title":"The characteristics of juvenile myasthenia gravis among South Africans","volume":"102","author":"Heckmann","year":"2012","journal-title":"S Afr Med J"},{"key":"10.1016\/j.nmd.2014.02.010_b0070","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.4049\/jimmunol.133.5.2479","article-title":"Pharmacokinetics and pharmacodynamics of three different prednisolone prodrugs: effect on circulating lymphocyte subsets and function","volume":"133","author":"Frey","year":"1984","journal-title":"J Immunol"},{"key":"10.1016\/j.nmd.2014.02.010_b0075","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2125.1986.tb05173.x","article-title":"The dose-dependent systemic availability of prednisone: one reason for the reduced biological effect of alternate-day prednisone","volume":"21","author":"Frey","year":"1986","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.nmd.2014.02.010_b0080","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1365-2249.1996.tb08306.x","article-title":"Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes","volume":"103","author":"Lanza","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.nmd.2014.02.010_b0085","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1513\/pats.200402-015MS","article-title":"Post-transcriptional and nongenomic effects of glucocorticoids","volume":"1","author":"Stellato","year":"2004","journal-title":"Proc Am Thorac Soc"},{"key":"10.1016\/j.nmd.2014.02.010_b0090","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1124\/jpet.104.074815","article-title":"Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines","volume":"312","author":"Thomas","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.nmd.2014.02.010_b0095","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jneuroim.2009.11.001","article-title":"Modulating dendritic cells (DC) from immunogenic to tolerogenic responses: a novel mechanism of AZA\/6-MP","volume":"218","author":"Aldinucci","year":"2010","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.nmd.2014.02.010_b0100","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/gut.2008.157339","article-title":"Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines","volume":"58","author":"Ben-Horin","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.nmd.2014.02.010_b0105","doi-asserted-by":"crossref","first-page":"640","DOI":"10.4049\/jimmunol.176.1.640","article-title":"Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins","volume":"176","author":"Poppe","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.nmd.2014.02.010_b0110","doi-asserted-by":"crossref","first-page":"41611","DOI":"10.1074\/jbc.M407981200","volume":"279","author":"Mason","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nmd.2014.02.010_b0115","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.bbrc.2008.11.153","article-title":"Cyclosporine A aggravates vascular endothelial injury in hyperlipidemic rats by down-regulating decay-accelerating factor","volume":"379","author":"Wang","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.nmd.2014.02.010_b0210","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1681\/ASN.2006060568","article-title":"Molecular mechanisms of cyclosporin A inhibition of the cytokine-induced matrix metalloproteinase-9 in glomerular mesangial cells","volume":"18","author":"Doller","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nmd.2014.02.010_b0125","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1172\/JCI109656","article-title":"Reduced rate of DNA replication fork movement in megaloblastic anemia","volume":"65","author":"Wickremasinghe","year":"1980","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nmd.2014.02.010_b0130","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1172\/JCI2676","article-title":"Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells","volume":"102","author":"Genestier","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nmd.2014.02.010_b0135","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1046\/j.1365-2249.2002.01777.x","article-title":"Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs","volume":"128","author":"Strauss","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.nmd.2014.02.010_b0140","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.4049\/jimmunol.167.5.2911","article-title":"Methotrexate suppresses NF-kappaB activation through inhibition of IkappaBalpha phosphorylation and degradation","volume":"167","author":"Majumdar","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.nmd.2014.02.010_b0145","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1074\/jbc.M407403200","article-title":"Prostaglandin E2 regulates the complement inhibitor CD55\/decay-accelerating factor in colorectal cancer","volume":"280","author":"Holla","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nmd.2014.02.010_b0150","doi-asserted-by":"crossref","first-page":"9113","DOI":"10.1128\/MCB.20.24.9113-9119.2000","article-title":"Functional consequences of a polymorphism affecting NF-kappaB p50\u2013p50 binding to the TNF promoter region","volume":"20","author":"Udalova","year":"2000","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.nmd.2014.02.010_b0155","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1128\/MCB.18.3.1266","article-title":"Functional interference of Sp1 and NF-kappaB through the same DNA binding site","volume":"18","author":"Hirano","year":"1998","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.nmd.2014.02.010_b0160","first-page":"6570","article-title":"An interaction between the DNA-binding domains of RelA(p65) and Sp1 mediates human immunodeficiency virus gene activation","volume":"14","author":"Perkins","year":"1994","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.nmd.2014.02.010_b0165","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.4049\/jimmunol.177.6.3837","article-title":"Constitutive expression of murine decay-accelerating factor 1 is controlled by the transcription factor Sp1","volume":"177","author":"Cauvi","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.nmd.2014.02.010_b0170","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.4049\/jimmunol.156.9.3402","article-title":"Human skeletal myoblasts spontaneously activate allogeneic complement but are resistant to killing","volume":"156","author":"Gasque","year":"1996","journal-title":"J Immunol"},{"key":"10.1016\/j.nmd.2014.02.010_b0175","doi-asserted-by":"crossref","first-page":"12062","DOI":"10.1073\/pnas.211257298","article-title":"Extraocular muscle is defined by a fundamentally distinct gene expression profile","volume":"98","author":"Porter","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.nmd.2014.02.010_b0180","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nmd.2014.02.010_b0185","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1073\/pnas.97.8.3919","article-title":"Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell","volume":"97","author":"De Bosscher","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.nmd.2014.02.010_b0190","doi-asserted-by":"crossref","first-page":"9126","DOI":"10.1128\/MCB.00679-06","article-title":"Glucocorticoids regulate tristetraprolin synthesis and posttranscriptionally regulate tumor necrosis factor alpha inflammatory signaling","volume":"26","author":"Smoak","year":"2006","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.nmd.2014.02.010_b0195","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1016\/j.molimm.2010.07.002","article-title":"Binding of human antigen R (HuR) to an AU-rich element (ARE) in the 3\u2032untranslated region (3\u2032UTR) reduces the expression of decay accelerating factor (DAF)","volume":"47","author":"Gray","year":"2010","journal-title":"Mol Immunol"},{"key":"10.1016\/j.nmd.2014.02.010_b0200","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1471-2377-11-97","article-title":"A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis","volume":"11","author":"Heckmann","year":"2011","journal-title":"BMC Neurol"},{"key":"10.1016\/j.nmd.2014.02.010_b0205","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0014-5793(97)00930-7","article-title":"Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-kappaB activation","volume":"413","author":"Meyer","year":"1997","journal-title":"FEBS Lett"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896614000753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896614000753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:02:22Z","timestamp":1760774542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896614000753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0960896614000753"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2014.02.010","relation":{},"ISSN":["0960-8966"],"issn-type":[{"type":"print","value":"0960-8966"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of prednisone and steroid-sparing agents on decay accelerating factor (CD55) expression: Implications in myasthenia gravis","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2014.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}